Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Gilenya Approved With Advisory Panel-Enhanced REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA follows the advice of its Peripheral and Central Nervous System Drugs Advisory Committee to ask doctors to do a range of testing and monitoring when they prescribe the MS drug.

You may also be interested in...



Biogen Idec’s BG-12 Results Up The Ante In The Oral MS Market

The competitive profile of Biogen Idec Inc.’s BG-12 in the highly coveted and burgeoning market for oral multiple sclerosis drugs got a big boost April 21 with the release of better-than-expected additional monotherapy data from the Phase III DEFINE study.

Biogen Idec’s BG-12 Results Up The Ante In The Oral MS Market

The competitive profile of Biogen Idec Inc.’s BG-12 in the highly coveted and burgeoning market for oral multiple sclerosis drugs got a big boost April 21 with the release of better-than-expected additional monotherapy data from the Phase III DEFINE study.

Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market

Biogen's drug is poised to become top dog among many oral MS drugs, including Novartis' approved Gilenya, analysts say.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel